Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nirogacestat Hydrobromide,Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : SpringWorks Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : In this collaboration, Applied BioMath is developing a model of SpringWorks' investigational oral selective small molecule gamma secretase inhibitor, nirogacestat (PF-03084014), in combination with an agent that targets B-cell maturation antigen for mult...
Product Name : PF-03084014
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 11, 2022
Lead Product(s) : Nirogacestat Hydrobromide,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : SpringWorks Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : CLN-049
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Cullinan Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Applied BioMath, LLC Announces Collaboration with Cullinan Oncology
Details : Applied BioMath will develop a systems pharmacology model for CLN-049, a novel FLT3XCD3 bispecific antibody for Acute Myeloid Leukemia, being developed by Cullinan Florentine, a Cullinan Oncology company.
Product Name : CLN-049
Product Type : Antibody
Upfront Cash : Undisclosed
September 29, 2020
Lead Product(s) : CLN-049
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Cullinan Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : OncoMyx Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Applied BioMath will develop a systems pharmacology model to mechanistically evaluate the pharmacokinetics and pharmacodynamics of OncoMyx's MYXV platform and therapeutic programs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 14, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : OncoMyx Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration